Skip to main content
. Author manuscript; available in PMC: 2015 Jun 15.
Published in final edited form as: Cancer. 2014 Mar 13;120(12):1780–1786. doi: 10.1002/cncr.28648

Figure 2.

Figure 2

In patients specifically treated with bevacizumab, a baseline serum albumin (b-alb) level ≥ 3.4 g/dL was found to be associated with a significant improvement in (Top) overall survival (median, 10.2 months vs 4.1 months; hazards ratio, 2.1 [P =.0001]) and (Bottom) time to disease progression (median 6.2 months vs 3.7 months; hazards ratio, 1.8 [P = .00488]).